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A B S T R A C T
Background: Limited and conﬂicting data exist for the inﬂuence of antiepileptic drugs on thyroid function
in children.
Objective: The aim of this study was to investigate the effects of phenobarbital, valproate,
carbamazepine, oxcarbazepine, and levetiracetam monotherapy on thyroid function in daily clinical
practice during a 12-month treatment period.
Method: A total of 223 children (103 females and 120 males) with new onset and controlled epilepsy
treated with valproate (n = 129), phenobarbital (n = 33), carbamazepine (n = 36), oxcarbazepine (n = 14),
levetiracetam (n = 11) were enrolled in the study. Serum free thyroxine (fT4) and thyroid-stimulating
hormone (TSH) levels were measured before and at ﬁrst, sixth and twelfth months of therapy.
Results: At baseline, average fT4 and TSH concentrations were not different between the drug groups.
Valproate-treated patients had decreased fT4 and increased TSH levels at months 1, 6, and 12.
Carbamazepine-treated patients had decreased fT4 levels at months 1, 6, and 12 and increased TSH levels
at months 1, and 6. Phenobarbital-treated patients had decreased fT4 levels at months 1, and 6, and
increased TSH levels at months 6 and 12. Oxcarbazepine-treated patients had decreased fT4 levels at
month 1. Levetiracetam-treated patients showed no signiﬁcant change of fT4 and TSH at any times. The
frequency of subclinical hypothyroidism at month 12 was 28% in valproate, 21.4% in oxcarbazepine,
18.2% in phenobarbital, 13.9% in carbamazepine, and 0% in levetiracetam groups.
Conclusion: Our data suggest that all antiepileptic drugs studied except levetiracetam had varying
degrees of deleterious effects on thyroid function.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
It is well-known that administration of antiepileptic drugs
(AEDs) may disturb thyroid function in adults.1 However, there are
limited and conﬂicting data about the inﬂuence of AEDs on thyroid
function in children.2–5
Valproate, carbamazepine and phenobarbital are effective and
widely used antiepileptic drugs for the treatment of many types of
epilepsy in children.6 Levetiracetam and oxcarbazepine are newer§ Institutional ethic number is 28.3.2013/17.
Abbreviations: AED, antiepileptic drug; fT4, free thyroxine; TSH, thyroid stimulating
hormone.
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1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.09.006AEDs, that are increasingly used as monotherapy as well as add-on
therapy in children.
The effect of valproate on serum thyroid hormone concen-
trations has been controversial. Elevated levels of thyroid-
stimulating hormone (TSH) have been demonstrated in some
studies,2–5,7–9 but not in others.10–13 Carbamazepine typically
causes reduced levels of free thyroxine (fT4), but has variable
effects on levels of TSH.3,8,11,12,14–16 Oxcarbazepine, a 10-keto
analog of carbamazepine, was developed to attempt to reduce
the side effects that have been observed with administration of
carbamazepine. A few studies focused on its effects on thyroid
function showed similar, but milder effects when compared to
carbamazepine.3,4,11,17 There have been few studies investigat-
ing the effect of phenobarbital on thyroid function, which
appears similar to those of carbamazepine and oxcarbazepine,
although of smaller magnitude.2,8,12,16,18 Levetiracetam is
effective for both focal and generalized epilepsy. However very
limited data exist on thyroid function in children treated with
levetiracetam.vier Ltd. All rights reserved.
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medications result in subclinical hypothyroidism which is deﬁned
as a mild elevation of TSH levels (5–25 mIU/l) in the presence of
normal thyroid hormone concentrations.8,19 Subclinical hypothy-
roidism appears to be a benign and remitting disease with a low
risk of evolution toward overt hypothyroidism and no effects on
neuropsychological functions.20 However its association with
oxcarbazepine treatment may lead overt hypothyroidism.21
Although the need for treatment of subclinical hypothyroidism
remains controversial,22 replacement therapy is not justiﬁed in
children with a TSH concentration between 5 and 10 mIU/l, no
goiter, and negative antithyroid antibodies.20
The results of the few studies investigating the effects of
carbamazepine and valproate on thyroid function in children with
epilepsy have been controversial.3–5,14,23 Moreover limited data
are available for the effects of phenobarbital, oxcarbazepine and
levetiracetam on thyroid function in children. Therefore, we aimed
to investigate the alterations in serum fT4 and TSH levels and the
frequency of subclinical hypothyroidism in children with new
onset epilepsy during a 12-month period of treatment with
phenobarbital, valproate, carbamazepine, oxcarbazepin and leve-
tiracetam monotherapy.
2. Methods
2.1. Patients
Hospital charts of children ages 3 months to 18 years who
admitted to pediatric neurology out-patient clinic at Dr. Behc¸et Uz
Children’s hospital between 1 July 2011 and 1 May 2013 were
retrospectively reviewed. Children who were diagnosed with new
onset idiopathic partial and generalized epilepsy, who received
phenobarbital, valproate, carbamazepine, oxcarbazepine, and
levetiracetam monotherapy and who were seizure free for at
least 12 months were identiﬁed. All children were developmen-
tally normal. Children those with progressive neurologic, thyroid
or other metabolic diseases; those with refractory seizures; who
had received any drug within the past 6 months that could affect
thyroid function; those with a family history of hypothyroidism or
endocrine dysfunction; or those with evidence of persistent
nonadherence to medication therapy were excluded from the
study. Since excess body weight can inﬂuence thyroid function,
subjects were excluded in the study if the body mass index was
95th percentile for age and gender. Institutional Ethical
Commitee approved the study.
During the study period, each patient was assessed and
followed up by the same child neurologist according to a standard
protocol that required the systematic control of fT4 and TSH levels
before the beginning of AED treatment and at the ﬁrst, sixth and
twelfth months of therapy. Blood samples were taken between 8
AM and 10 AM after an overnight fast and measurement of fT4 and
TSH levels were performed on the same day. All hormonal analyses
were performed using commercial enzymatic methods at baseline
or during the study period (Roche Diagnostics, Mannheim,
Germany).
Detailed information including demographic characteristics,
seizure type, seizure etiology, epileptic syndrome, age at onset,
selected AED, and duration of AED therapy were collected. New
onset epilepsy was deﬁned as two or more unprovoked seizures.
Seizure types, etiology and epilepsy syndromes were classiﬁed
according to the recommendations of the International League
Against Epilepsy.24 The electroencephalography ﬁndings of all
patients were interpreted by the same physician and categorized
as normal, and abnormal with epileptic activity.
Antiepileptic drugs were selected by the physician on the basis
of the type of epilepsy and the physician’s experience. Valproatewas used primarily for patients with primary generalized seizures
who are older than two years of age; phenobarbital was used
primarily in children younger than two years of age; and
carbamazepine, oxcarbazepine and levetiracetam were chosen
primarily for patients with partial seizures with or without
generalizations. Dosage of AEDs, seizure control, and serum levels
of valproate, carbamazepine and phenobarbital were recorded at
each visit. All AEDs were prescribed at the recommended dosages,
and all were administered in two daily doses. The doses of AEDs
were adjusted according to the clinical response and tolerability
during follow-up.
Subclinical hypothyroidism was classiﬁed according to the
grading system deﬁned by Staub et al.25 grade I, TSH greater than
the upper limit of our laboratory (4.99 mIU/ml in this study) and
<6 mIU/ml; grade II, TSH between 6 and 12 mIU/ml; and grade III,
TSH >12 mIU/ml. Patients with grade III subclinical hypothyroid-
ism were evaluated by a pediatric endocrinologist, and low-dose L-
tyroxine replacement therapy was initiated in one patient, and the
data of this patient at 6th and 12th months were not included into
the analysis. Serum fT4 concentration has been considered low
when it was lower than 1.0 ng/ml, which was the lower limit of our
laboratory’s normal reference ranges.
2.2. Statistical analysis
Values are expressed as mean  standard deviation (SD), and
analyzed using SPSS for Windows software package, version 20.0
(SPSS, Chicago, IL). Frequencies and means were calculated by
descriptive analysis. For categorical variables, x2 was used for
comparing independent group differences, and Mc Nemar x2 test for
comparing related group differences. The differences in the mean
serum concentrations of the thyroid hormones between the ﬁve
patient groups were analyzed by the Kruskal–Wallis test. The data of
the patients at different times of the study (at baseline and at the 1st,
6th, and 12th months) were evaluated by the Friedman test, with a
Bonferroni post hoc test. p Values less than 0.05 were considered
statistically signiﬁcant.
3. Results
A total of 223 children consisting of 103 (46.2%) females and
120 (53.8%) males were enrolled in the study. The clinical
characteristics of the children participating in the study are
shown in Table 1.
Of the 223 children, 33 (14.8%) were receiving phenobarbital,
129 (57.8%) were receiving valproate, 36 (16.1%) were receiving
carbamazepine, 14 (6.3%) were receiving oxcarbazepine, and 11
(4.9%) were receiving levetiracetam monotherapy. All patients
receiving phenobarbital, valproate, and carbamazepine had drug
concentrations at a therapeutic level.
Serum fT4 and TSH concentrations at baseline and at the ﬁrst,
sixth and twelfth months of AEDs treatment are shown in Tables 2
and 3, respectively. There was no signiﬁcant difference in the
average fT4 and TSH concentrations between the AED groups
before the initiation of therapy. At ﬁrst month of therapy, however,
serum fT4 levels were found signiﬁcantly decreased in carbamaz-
epine and oxcarbamazepine groups when compared with other
groups. At sixth month of therapy, a signiﬁcantly lower serum FT4
levels were found in phenobarbital, carbamazepine and oxcarba-
mazepine groups when compared with levetiracetam and
valproate groups. At twelfth month of therapy, serum fT4 levels
were found signiﬁcantly lower only in carbamazepine group when
compared with phenobarbital, valproate and levetiracetam groups.
When we analyzed the serum TSH levels between groups,
signiﬁcantly higher levels were found in valproate group when
compared with phenobarbital, carbamazepine and levetiracetam
Table 1
Characteristics of the patients treated with ﬁrst-line antiepileptic drug monotherapy.
Characteristics Total n = 223(%) Phenobarbital
n = 33 (15%)
Valproate
n = 129(58%)
Carbamazepine
n = 36 (16%)
Oxcarbazepine
n = 14 (6%)
Levetiracetam
n = 11(5%)
p value
Female, n (%) 103 (46.2) 19 (57.6) 53 (41.1) 18 (50.0) 6 (42.9) 7 (63.6) 0.320
Male, n (%) 120 (53.8) 14 (42.4) 76 (58.9) 18 (50.0) 8 (57.1) 4 (36.4)
Age at onset, yrs;
mean, SD, range
6.08  4.41 (0.3–16) 1.11  1.16 (0.3–3) 6.50  4.19 (1–15) 8.55  4.10 (1–16) 5.5  3.45 (1–11) 8.81  3.78 (2–15) <0.001
Age groups <0.001
<1, n (%) 22 (9.9) 18 (54.5) 3 (2.3) 1 (2.8) 0 0
1–6, n (%) 105 (47.1) 15 (45.5) 63 (52.7) 11 (30.6) 8 (57.1) 3 (27.3)
6–12, n (%) 65 (29.1) 0 37 (28.7) 16 (44.4) 6 (42.9) 6 (54.5)
>12, n (%) 31 (13.9) 0 21 (16.3) 8 (22.2) 0 2 (18.2)
Seizure type 0.001
Generalized 146 (65.5) 28 (84.8) 89 (69.0) 18 (50.0) 7 (50.0) 4 (36.4)
Partial 74 (32.2) 3 (9.1) 40 (31.0) 17 (47.2) 7 (50.0) 7 (63.6)
Unknown 3 (1.3) 2 (6.1) 1 (2.8)
EEG 0.144
Normal 77 (34.5) 16 (48.5) 47 (36.4) 9 (25.0) 3 (21.4) 2 (18.2)
Epileptic 146 (65.5) 17 (51.5) 82 (63.6) 27 (75.0) 11 (78.6) 9 (81.8)
p: differences between drug groups.
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levetiracetam group at the sixth month; and in valproate,
oxcarbazepine and phenobarbital groups when compared with
levetiracetam group, and in valproate group when compared with
carbamazepine group at the twelfth months.Table 3
Average TSH values (mean  SD) at various times for groups divided according to antiepi
Time Total (n = 223) Phenobarbital
(n = 33)
Valproate
(n = 129)
Baseline 3.04  1.34 2.81  1.09 3.11  1.39 
Month 1 4.04  2.25 3.16  1.07 4.45  2.48 
p value <0.001b 0.046b <0.001b
Month 6 4.13  2.21 3.56  1.60 4.42  2.23 
p value <0.001b <0.001b <0.001b
Month 12 3.96  2.12 3.70  1.52 4.28  2.32 
p value <0.001b 0.001b <0.001b
p value <0.001a <0.001a <0.001a
a p: differences between repeated measures at baseline and at ﬁrst, sixth and twelft
b p: pairwise comparisons of TSH values at ﬁrst, sixth and twelfth months individua
c p: differences between drug groups at baseline and at ﬁrst, sixth and twelfth mon
Pairwise comparisons showed no signiﬁcant difference between TSH concentrations at m
Signiﬁcant differences between drug groups at various times demonstrated by pairwis
 at 1st month; FB-VPA (0.005), VPA-LEV (0.020), CRZ-VPA (0.045).
 at 6th month; VPA-LEV (0.012).
 at 12th month; VPA-LEV (0.002), LEV-OXC (0.040), LEV-FB (0.029), CRZ-VPA (0.031).
Table 2
Average fT4 values (mean  SD) at various times for groups divided according to antiepil
Time Total (n = 223) Phenobarbital (n = 33) Valproate (n = 129) Carba
Baseline 1.25  0.19 1.20  0.12 1.29  0.21 1.21 
Month 1 1.16  0.18 1.14  0.15 1.21  0.18 1.06 
p value <0.001b 0.004b <0.001b 0.002
Month 6 1.17  0.16 1.13  0.11 1.20  0.17 1.05 
p value <0.001b <0.001b <0.001b <0.00
Month 12 1.17  0.17 1.19  0.16 1.19  0.17 1.06 
p value <0.001b 0.916b <0.001b <0.00
p value <0.001a <0.001a <0.001a <0.00
a p: differences between repeated measures at baseline and at ﬁrst, sixth and twelft
b p: pairwise comparisons of fT4 values at ﬁrst, sixth and twelfth months individual
c p: differences between drug groups at baseline and at ﬁrst, sixth and twelfth mon
Pairwise comparisons showed no signiﬁcant difference between fT4 concentrations at m
Signiﬁcant differences between fT4 concentrations at month 1 and 6, 1 and 12, and 6 
 FB group: 6th month–12th month (0.046).
Signiﬁcant differences between drug groups at various times demonstrated by pairwis
 at 1st month; OXC-FB (0.014), OXC–LEV (0.013), OXC–VPA (<0.001), CRZ- FB (0.038)
 at 6th month; CRZ-VPA (<0.001), CRZ-LEV (<0.001), OXC–VPA (0.013), OXC -LEV (0.
 at 12th month; CRZ-VPA (<0.001), CRZ- FB (0.001), CRZ-LEV (0.003).Overall, serum fT4 levels tended to decrease at the ﬁrst month
of therapy and this reduction persisted throughout 12-month
period. In patients treated with phenobarbital, serum fT4 levels
were found signiﬁcantly decreased at ﬁrst and sixth months of
treatment, however it was not signiﬁcantly different at twelfthleptic drugs being used (mIU/ml).
Carbamazepine
(n = 36)
Oxcarbazepine
(n = 14)
Levetiracetam
(n = 11)
p value
2.88  1.13 3.57  1.95 2.74  0.97 0.650c
3.57  1.65 4.48  3.09 2.89  1.11 0.010c
0.007b
4.11  2.73 3.86  2.16 2.84  0.76 0.039c
0.008b
3.37  1.54 4.22  2.70 2.57  0.84 0.015c
0.192b
0.003a 0.712a 0.914a
h months in each drug group.
lly with baseline values.
ths.
onth 1 and 6, 1 and 12, and 6 and 12 in each drug group (p > 0.05 for each analysis).
e comparisons, (p value):
eptic drugs being used (ng/ml).
mazepine (n = 36) Oxcarbazepine (n = 14) Levetiracetam (n = 11) p value
 0.18 1.18  0.12 1.25  0.21 0.096c
 0.14 1.01  0.13 1.19  0.21 <0.001c
b 0.001b
 0.13 1.09  0.11 1.32  0.21 <0.001c
1b 0.169b
 0.13 1.11  0.13 1.24  0.17 <0.001c
1b 0.094b
1a 0.001a 0.165a
h months in each drug group.
ly with baseline values.
ths.
onth 1 and 6, 1 and 12, and 6 and 12 in each drug group (p > 0.05 for each analysis).
and 12 in each drug group (p value).
e comparisons, (p value):
, CRZ-LEV (0.037), CRZ-VPA (<0.001).
002), FB -VPA (0.037), FB -LEV (0.007).
Fig. 1. The changes in serum fT4 and TSH concentrations in children receiving various antiepileptic drug monotherapy during the 12-month study period. (A) Serum fT4
concentrations decreased signiﬁcantly in children receiving phenobarbital, valproate, carbamazepine, and oxcarbazepine, and nonsigniﬁcantly in children receiving
levetiracetam at the ﬁrst month of therapy. This low level persisted throughout the 12-month study period in patients receiving valproate, carbamazepine and oxcarbazepine.
However fT4 concentrations returned to baseline levels in patients receiving phenobarbital at twelfth month. The changes were not signiﬁcant at any measurements in
patients receiving levetiracetam. (B) Serum TSH concentrations increased signiﬁcantly in children receiving valproate and carbamazepine, and nonsigniﬁcantly in children
receiving phenobarbital, oxcarbazepine and levetiracetam at the ﬁrst month of therapy. This high level persisted throughout the 12-month study period only in patients
receiving valproate. Serum TSH levels increased progresively in patients receiving phenobarbital and became signiﬁcant at sixth and twelfth months. In patients receiving
carbamazepine the increase was signiﬁcant at ﬁrst and sixth months, however it was nonsigniﬁcant at twelfth months. The changes were not signiﬁcant at any measurements
in patients receiving oxcarbazepine and levetiracetam.
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serum fT4 levels was signiﬁcant at ﬁrst, sixth and twelfth months
in patients treated with valproate and carbamazepine when
compared with baseline levels. In patients treated with oxcarba-
zepine, serum fT4 levels were found decreased signiﬁcantly at ﬁrst
month and insigniﬁcantly at sixth and twelfth months. Serum fT4
levels in patients treated with levetiracetam were not signiﬁcantly
different at any measurement when compared with baseline levels
(Table 2). Except for the change between values at sixth and
twelfth months in phenobarbital group, no signiﬁcant change of
fT4 levels were found in any drug groups throughout the study
period after the beginning of therapy (Fig. 1). At baseline 1 (3.0%)
patient in phenobarbital group, 5 (3.9%) patients in valproate
group, 3 (8.3%) patients in carbamazepine group, 1 (9.1%) patient in
levetiracetam group and no patient in oxcarbazepine group had
serum fT4 levels below the reference range. The frequency of low
serum fT4 levels was found signiﬁcantly increased at ﬁrst and
twelfth months and nonsigniﬁcantly increased at sixth month of
therapy in patients treated with valproate. The frequency of low
serum FT4 levels increased signiﬁcantly at ﬁrst, sixth and twelfth
months in patients treated carbamazepine when compared
baseline rate. It was signiﬁcantly higher at ﬁrst, and nonsigniﬁ-
cantly higher at sixth and twelfth months of therapy in patients
treated with phenobarbital and oxcarbazepine. The frequency of
low serum fT4 levels was not signiﬁcantly higher at any time in
patients treated with levetiracetam when compared with baseline
rates (Table 4).
Overall, serum TSH levels tended to increase at ﬁrst month of
therapy and these increased levels persisted throughout the study
period. Serum TSH levels increased signiﬁcantly at ﬁrst, sixth andTable 4
Frequency of low fT4 at various times for groups divided according to antiepileptic dr
Time Total n = 223 (%) Phenobarbital
n = 33 (%)
Valproate
n = 129 (%)
Baseline 10 (4.5) 1 (3.0) 5 (3.9) 
Month 1 42 (18.8) 8 (24.2) 12 (9.3) 
p value <0.001 0.016a 0.039a
Month 6 33 (14.9) 5 (15.2) 13 (10.2) 
p value <0.001 0.125a 0.057a
Month 12 34 (15.3) 4 (12.1) 16 (12.5) 
p value <0.001 0.250a 0.007a
a p: pairwise comparisons of the frequency of low fT4 levels at ﬁrst, sixth and twelf
b p: differences between drug groups at baseline and at ﬁrst, sixth and twelfth montwelfth months of therapy in patients receiving valproate and
phenobarbital. In children receiving carbamazepine, the increase
in serum TSH levels was signiﬁcant at ﬁrst and sixth months, but
not signiﬁcant at twelfth month of therapy. Serum TSH levels were
not signiﬁcantly different at any measurements when compared
with baseline levels in patients treated with oxcarbazepine and
levetiracetam (Table 3). After the ﬁrst month of therapy, no
signiﬁcant change of TSH levels were seen in any drug groups
(Fig. 1).
At baseline, 10 (7.8%) patients in valproate group, 1 (2.8%)
patient in carbamazepine group, 1 (7.1%) patient in oxcarbazepine
group and no patient in oxcarbazepine and phenobarbital groups
had serum TSH levels above the reference range of laboratory. The
frequency of high serum TSH levels increased signiﬁcantly at ﬁrst,
sixth and twelfth months in patients treated with valproate. It
increased signiﬁcantly at ﬁrst and sixth months, and nonsigniﬁ-
cantly at twelfth month in patients treated with carbamazepine.
However no signiﬁcant difference in the frequency of high serum
TSH values in patients treated with phenobarbital, oxcarbazapine
and levetiracetam was detected at the ﬁrst, sixth and twelfth
months when compared with baseline rates (Table 5).
4. Discussion
Antiepileptic drugs affect thyroid hormone levels through
several mechanisms. Many of them increase hepatic microsomal
enzyme systems, thus accelerating clearance of thyroid hormone,
others interfere with the hypothalamic–pituitary axis.26,27 This
study investigated the effects of widely used AEDs that included
phenobarbital, valproate, carbamazepine, oxcarbazepine andugs being used.
Carbamazepine
n = 36 (%)
Oxcarbazepine
n = 14 (%)
Levetiracetam
n = 11 (%)
p Value
3 (8.3) 0 1 (9.1) 0.605b
13 (36.1) 6 (42.9) 3 (27.3) <0.001b
0.006a 0.031a 0.500a
12 (33.3) 3 (21.4) 0 0.006b
0.004a 0.250a 1.0a
12 (33.3) 2 (14.3) 0 0.017b
0.004a 0.500a 1.0a
th months individually with baseline rates.
ths.
Table 5
Frequency of high TSH at various times for groups divided according to antiepileptic drugs being used.
Time Total n = 223 (%) Phenobarbital
n = 33 (%)
Valproate
n = 129 (%)
Carbamazepine
n = 36 (%)
Oxcarbazepine
n = 14 (%)
Levetiracetam
n = 11 (%)
p value
Baseline 12 (5.4) 0 10 (7.8) 1 (2.8) 1 (7.1) 0 0.344b
Grade1 8 (3.6) 0 7 (5.4) 1 (2.8) 0 0
Grade2 4 (1.8) 0 3 (2.3) 0 1 (7.1) 0
Grade3 0/223 0 0 0 0 0
Month 1 51 (22.9) 2 (6.1) 37 (28.7) 7 (19.4) 5 (35.7) 0/11 0.014b
p value <0.001 0.500a <0.001a 0.031a 0.125a
Grade1 16 (7.2) 2 (6.1) 9 (7.0) 5 (13.9) 0 0
Grade2 32 (14.3) 0 25 (19.4) 2 (5.6) 5 (35.7) 0
Grade3 3 (1.3) 0 3 (2.3) 0 0 0
Month 6 61 (27.5) 4 (12.1) 45 (35.2) 10 (27.8) 2 (14.3) 0/11 0.011b
p value <0.001 0.125a <0.001a 0.004a 1.0a
Grade1 26 (11.7) 1 (3.0) 21 (16.4) 4 (11.1) 0 0
Grade2 33 (14.9) 3 (9.1) 23 (18.0) 5 (13.9) 2 (14.3) 0
Grade3 2 (0.9) 0 1 (0.8) 1 (2.8) 0 0
Month 12 51 (23.0) 6 (18.2) 37 (28.9) 5 (13.9) 3 (21.4) 0/11 0.093b
p value <0.001 0.31a <0.001a 0.125a 0.500a
Grade1 24 (10.8) 3 (9.1) 16 (12.5) 4 (11.1) 1 (7.1) 0
Grade2 25 (11.3) 3 (9.1) 19 (14.8) 1 (2.8) 2 (14.3) 0
Grade3 2 (0.9) 0 2 (1.6) 0 0 0
a p: pairwise comparisons of the frequency of high TSH levels at ﬁrst, sixth and twelfth months individually with baseline rates.
b p: differences between drug groups at baseline and at ﬁrst, sixth and twelfth months.
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period of therapy. In accordance with previous studies,2,4,14,18 all of
the AEDs studied except levetiracetam affected thyroid function
with varying degrees during the 12-month period of treatment.
The present study showed a signiﬁcant increase in the TSH
concentrations, and a signiﬁcant reduction in the fT4 concentra-
tions in patients treated with valproate; and these changes
persisted throughout the 12-month study period. Similarly, both
signiﬁcantly decreased fT4 levels and signiﬁcantly increased TSH
levels were previously reported in patients during valproate
therapy.3,7,8,23,28 In a study of adolescent girls with epilepsy,
valproate receiving group showed higher levels of TSH and lower
levels of fT4 than did the untreated group, although still within
normal range.10 In other studies, however, fT4 levels were found to
be unchanged while TSH levels increased in patients using
valproate.3,4,9,11 On the contrary, some other studies have
demonstrated that both fT4 and TSH concentrations were
unaffected in patients treated with valproate1,11,13,14,16 Similar
with our results, the frequency of subclinical hypothyroidism was
reported at a rate of 25.2% in patients treated with valproate, and it
was found higher in patients with a duration of treatment between
6 and 24 months than those receiving valproate for less than 6
months or for more than 2 years.7 Another study has shown that
prolonged duration of valproate therapy for more than 24 months
was associated with higher risk of subclinical hypothyroidism.9
We did not observe an increase in frequency of subclinical
hypothyroidism after the ﬁrst month of therapy, instead it
remained relatively stable during the rest of the study period.
Several previous studies have shown that the reduced fT4 and
increased TSH concentrations returned to normal values after the
withdrawal of valproate.2,3,23 Thus, the changes induced by long
term administration of valproate appear to be transient and
reversible.
Carbamazepine is known to accelerate the metabolism of
thyroid hormones by inducing of the hepatic P450 enzyme system
which causes increased metabolism of thyroid hormones, and by
interfering with thyroid hormone competitive binding to thyroid-
binding globulin.3 In the present study, children received
carbamazepine showed a signiﬁcant reduction in fT4 concentra-
tions throughout the 12-month period and signiﬁcantly increased
TSH concentrations at the ﬁrst and sixth months of therapy.Similarly, a previous study showed a signiﬁcant reduction in the
levels of fT4 and a signiﬁcant increase in the levels of TSH in
children treated with carbamazepine.2 In our study, although
serum TSH concentration was still higher than the baseline values
in children receiving carbamazepine, the difference was not
signiﬁcant anymore at the twelfth month of therapy. This ﬁnding
was in line with a previous study which has shown that TSH levels
increased during the ﬁrst 4–20 days of treatment, and then
declined rapidly to normal levels.29 The changes induced by
carbamazepine appear to return to normal values after the
withdrawal of medication.2,3,30 Subclinical hypothyroidism was
previously reported in 8.2% of 61 children receiving carbamaze-
pine.8 We found a relatively higher frequency of subclinical
hypothyroidism in patients receiving carbamazepine (19.% at the
ﬁrst month, 27.8% at the sixth month and 13.9% at the twelfth
month).
Oxcarbazepine, despite its close structural resemblance, does
not induce enzyme activity to a similar extend as does
carbamazepine.17 Indeed, low serum thyroid hormone levels
induced by carbamazepine have been shown to normalize after
replacement of carbamazepine with oxcarbazepine in adults.11
Several studies have demonstrated that serum fT4 levels were
signiﬁcantly reduced in patients receiving oxcarbazepine, whereas
TSH concentrations remained unchanged in children.2–4 In
consistent with these reports, in the present study, serum fT4
concentrations decreased signiﬁcantly at the ﬁrst month of
therapy, and these low levels persisted throughout the 12-month
study period, whereas the increase in TSH concentration was
insigniﬁcant. Similarly, a previous study revealed reduced fT4
levels occurring in the early stages of oxcarbazepine therapy in
children.4 Moreover, subclinical hypothyroidism associated with
oxcarbazepine treatment may lead overt hypothyroidism.21 By
contrast, another study has reported short-term oxcarbazepine
treatment in adults had no deleterious effect on thyroid hormone
status.31 In addition, the reduced fT4 concentrations were found to
return to normal values after the withdrawal of oxcarbazepine.3
Thus, it appears that the effect of oxcarbazepine on thyroid
function is short term, transient and less signiﬁcant than the effect
of carbamazepine.
Children with epilepsy during chronic treatment with pheno-
barbital were found to have signiﬁcantly reduced fT4 levels but
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By contrast, another study has demonstrated no signiﬁcant
differences in serum fT4 and TSH levels between the patients
receiving phenobarbital and the control group.18 Phenobarbital
was found to lower T3 and T4 levels only when it has been used for
longer than six years.16 In our series, serum fT4 concentrations in
patients receiving phenobarbital were found signiﬁcantly reduced
at the ﬁrst and sixth months, however this reduction did not
persist at twelfth month. By contrast serum TSH levels showed a
signiﬁcant and progressive increase throughout the 12-month
treatment. However the changes on THS concentrations were less
marked than those in patients treated with valproate. A previous
study has shown that the increased TSH concentrations returned to
normal values after the withdrawal of phenobarbital.2 Thus, the
effects of phenobarbital on thyroid function appear reversible.
Levetiracetam is considered to have fewer side effects than
older AEDs. However, data on the effects of levetiracetam on
thyroid function are scant. In a recent study, thyroid function were
found unaffected in ﬁve children receiving levetiracetam during a
9-month period.18 In consistent with this report, fT4 and TSH levels
were found unchanged in our patients receiving levetiracetam
during the 12-month period of observation.
In the limited number of studies, the prevalence of subclinical
hypothyroidism in children was reported to be slightly lower than
2%.32 In studies investigating the effects of AEDs on thyroid
function, the frequency of subclinical hypothyroidism in healthy
controlled children have been found between 0% and 7.7%.2,7–9 In
our series, overall 12 (5.4%) patients had serum TSH levels above
the reference range before the beginning of antiepileptic therapy.
The exact pathogenic mechanisms underlying the association
between epilepsy and disturbed thyroid function have not been
fully elucidated. The relatively high frequency of subclinical
hypothyroidism in epileptic children before the initiation of
antiepileptic medication may suggest that epilepsy itself has a role
on thyroid function, as some researchers claim that epilepsy plays
a pathogenic role in the occurrence of endocrine disorders.33,34
Obviously this controversial issue needs to be clariﬁed with further
studies.
4.1. Limitations
One of the limitations of our study was that we were not able to
form a control group because of ethical reasons. This limitation
may be omitted with using baseline values as controls. As a
retrospective study, we were constrained by the information
available on the medical records. However, a standard protocol
that required the systematic control of fT4 and TSH levels before
the beginning of antiepileptic treatment and at the ﬁrst, sixth and
twelfth months of AED treatment lessened the effect of this
limitation. Moreover all patients in the study group have been
assessed and followed-up by a single child neurologist (U.Y.) who
also recorded all measurements on patients’ charts, which further
lessened the effect of retrospective design of the study. Another
limitation of the study was the lack of adjustment of fT4 and TSH
values for body mass index. It has previously been shown that
serum TSH were positively and FT4 was negatively associated with
BMI in healthy euthyroid children.35 We have excluded patients if
the body mass index was 95th percentile for age and gender at
baseline, however we did not adjust fT4 and TSH measurements for
body mass index in the analysis due to the lack of data for height of
the patients at ﬁrst, sixth, and twelfth months of study period. The
small sample size of oxcarbazepine and levetiracetam groups was
the other limitation of the study. While valproate, carbamazepine
and phenobarbital are widely used ﬁrst-line AEDs in daily clinical
practice, levetiracetam and oxcarbazepine are recently began to be
used in the initial treatment of childhood epilepsy. For this reason,numbers of children receiving these AEDs were small, and ﬁndings
presented in this study may be regarded as preliminary data for the
effects of levetiracetam and oxcarbazapine on thyroid function in
children. Further studies with larger samples are needed to clarify
the effects of these AEDs on thyroid function.
5. Conclusion
In conclusion, all AEDs except levetiracetam studied had
deleterious effects on thyroid function with varying degrees in
children during the period of 12-month therapy. The effects on
thyroid function induced by valproate and carbamazepine appear
to be more marked than those induced by phenobarbital and
oxcarbazepine. Therefore, evaluation of thyroid function should be
considered in children receiving valproate and carbamazepine
monotherapy.
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